Swapna Mahurkar-Joshi1, Carl Robert Rankin2, Elizabeth Jane Videlock1, Artin Soroosh2, Abhishek Verma1, Ariela Khandadash1, Dimitrios Iliopoulos2, Charalabos Pothoulakis2, Emeran A Mayer1, Lin Chang3. 1. G. Oppenheimer Center for Neurobiology of Stress and Resilience, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, California. 2. UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, California. 3. G. Oppenheimer Center for Neurobiology of Stress and Resilience, Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, California. Electronic address: linchang@mednet.ucla.edu.
Abstract
BACKGROUND & AIMS: Alterations in microRNA (miRNA) and in the intestinal barrier are putative risk factors for irritable bowel syndrome (IBS). We aimed to identify differentially expressed colonic mucosal miRNAs, their targets in IBS compared to healthy controls (HCs), and putative downstream pathways. METHODS: Twenty-nine IBS patients (15 IBS with constipation [IBS-C], 14 IBS with diarrhea [IBS-D]), and 15 age-matched HCs underwent sigmoidoscopy with biopsies. A nCounter array was used to assess biopsy specimen-associated miRNA levels. A false discovery rate (FDR) < 10% was considered significant. Real-time polymerase chain reaction (PCR) was used to validate differentially expressed genes. To assess barrier function, trans-epithelial electrical resistance (TEER) and dextran flux assays were performed on Caco-2 intestinal epithelial cells that were transfected with miRNA-inhibitors or control inhibitors. Protein expression of barrier function associated genes was confirmed using western blots. RESULTS: Four out of 247 miRNAs tested were differentially expressed in IBS compared to HCs (FDR < 10%). Real-time PCR validation suggested decreased levels of miR-219a-5p and miR-338-3p in IBS (P = .026 and P = .004), and IBS-C (P = .02 and P = .06) vs. HCs as the strongest associations. Inhibition of miR-219a-5p resulted in altered expression of proteasome/barrier function genes. Functionally, miR-219a-5p inhibition enhanced the permeability of intestinal epithelial cells as TEER was reduced (25-50%, P < .05) and dextran flux was increased (P < .01). Additionally, inhibition of miR-338-3p in cells caused alterations in the mitogen-activated protein kinase (MAPK) signaling pathway genes. CONCLUSION: Two microRNAs that potentially affect permeability and visceral nociception were identified to be altered in IBS patients. MiR-219a-5p and miR-338-3p potentially alter barrier function and visceral hypersensitivity via neuronal and MAPK signaling and could be therapeutic targets in IBS.
BACKGROUND & AIMS: Alterations in microRNA (miRNA) and in the intestinal barrier are putative risk factors for irritable bowel syndrome (IBS). We aimed to identify differentially expressed colonic mucosal miRNAs, their targets in IBS compared to healthy controls (HCs), and putative downstream pathways. METHODS: Twenty-nine IBS patients (15 IBS with constipation [IBS-C], 14 IBS with diarrhea [IBS-D]), and 15 age-matched HCs underwent sigmoidoscopy with biopsies. A nCounter array was used to assess biopsy specimen-associated miRNA levels. A false discovery rate (FDR) < 10% was considered significant. Real-time polymerase chain reaction (PCR) was used to validate differentially expressed genes. To assess barrier function, trans-epithelial electrical resistance (TEER) and dextran flux assays were performed on Caco-2 intestinal epithelial cells that were transfected with miRNA-inhibitors or control inhibitors. Protein expression of barrier function associated genes was confirmed using western blots. RESULTS: Four out of 247 miRNAs tested were differentially expressed in IBS compared to HCs (FDR < 10%). Real-time PCR validation suggested decreased levels of miR-219a-5p and miR-338-3p in IBS (P = .026 and P = .004), and IBS-C (P = .02 and P = .06) vs. HCs as the strongest associations. Inhibition of miR-219a-5p resulted in altered expression of proteasome/barrier function genes. Functionally, miR-219a-5p inhibition enhanced the permeability of intestinal epithelial cells as TEER was reduced (25-50%, P < .05) and dextran flux was increased (P < .01). Additionally, inhibition of miR-338-3p in cells caused alterations in the mitogen-activated protein kinase (MAPK) signaling pathway genes. CONCLUSION: Two microRNAs that potentially affect permeability and visceral nociception were identified to be altered in IBS patients. MiR-219a-5p and miR-338-3p potentially alter barrier function and visceral hypersensitivity via neuronal and MAPK signaling and could be therapeutic targets in IBS.
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Giovanni Barbara; Vincenzo Stanghellini; Roberto De Giorgio; Cesare Cremon; Graeme S Cottrell; Donatella Santini; Gianandrea Pasquinelli; Antonio M Morselli-Labate; Eileen F Grady; Nigel W Bunnett; Stephen M Collins; Roberto Corinaldesi Journal: Gastroenterology Date: 2004-03 Impact factor: 22.682
Authors: Carolin Wohlfarth; Stefanie Schmitteckert; Janina D Härtle; Lesley A Houghton; Harsh Dweep; Marina Fortea; Ghazaleh Assadi; Alexander Braun; Tanja Mederer; Sarina Pöhner; Philip P Becker; Christine Fischer; Martin Granzow; Hubert Mönnikes; Emeran A Mayer; Gregory Sayuk; Guy Boeckxstaens; Mira M Wouters; Magnus Simrén; Greger Lindberg; Bodil Ohlsson; Peter Thelin Schmidt; Aldona Dlugosz; Lars Agreus; Anna Andreasson; Mauro D'Amato; Barbara Burwinkel; Justo Lorenzo Bermejo; Ralph Röth; Felix Lasitschka; Maria Vicario; Marco Metzger; Javier Santos; Gudrun A Rappold; Cristina Martinez; Beate Niesler Journal: Sci Rep Date: 2017-10-31 Impact factor: 4.379
Authors: Charlene Choo; Swapna Mahurkar-Joshi; Tien S Dong; Adrienne Lenhart; Venu Lagishetty; Jonathan P Jacobs; Jennifer S Labus; Nancee Jaffe; Emeran A Mayer; Lin Chang Journal: Am J Physiol Gastrointest Liver Physiol Date: 2022-06-21 Impact factor: 4.871
Authors: Luis Alberto Bravo-Vázquez; Ixchel Medina-Ríos; Luis David Márquez-Gallardo; Josué Reyes-Muñoz; Francisco I Serrano-Cano; Surajit Pathak; Antara Banerjee; Anindya Bandyopadhyay; Asim K Duttaroy; Sujay Paul Journal: Dig Dis Sci Date: 2022-05-04 Impact factor: 3.487
Authors: Susrutha Puthanmadhom Narayanan; Daniel R O'Brien; Mayank Sharma; Thomas C Smyrk; Rondell P Graham; Madhusudan Grover; Adil E Bharucha Journal: Clin Gastroenterol Hepatol Date: 2021-10-02 Impact factor: 13.576